To include your compound in the COVID-19 Resource Center, submit it here.

Combination therapy could treat tumors resistant to MAPK pathway inhibitors

In a study published in Nature Medicine, Genmab A/S (CSE:GEN; Pink:GMXAY) and academic researchers identified a combination therapy approach that could combat drug resistance in heterogeneous tumors.

Melanoma tumors with BRAF mutations that are --

Read the full 349 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE